Background : There were no published data regarding the clinical efficacy and safety of everolimus-eluting stent (EES) following primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). We evaluated the one-year outcome of everolimus-eluting stent versus 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-eluting stent) drug-eluting stents(DES) for the treatment of STEMI. Methods : A prospective, open-labeled, multi-center cohort has been performed at 4 centers in Korea. All patients will be clinically followed-up for two years. The primary endpoint was major adverse cardiac event (MACE): the composite of cardiac death (CD), recurrent MI and ischemia-driven target vessel revascularization (TVR) at 1 year. Stent thromboses (ST) by ARC definition were analyzed. Results : Total 797 patients (EES=197, ZES=203, SES=203, PES=194) who were completed more than one year were analyzed. One-year MACE were 2.0%, 5.9%, 3.4% and 5.7% in EES-, ZES-, SES- and PES-group, respectively (p=ns). Cardiac death was 1.0%, 2.5%, 1.5% and 1.0% in EES-, ZES-, SES- and PES-group, respectively (p=ns). ST was 0%, 2.0%, 2.0% and 2.0% in EES-, ZES-, SES- and PES- group, respectively (p=ns). Conclusions: Campared to 1st and 2nd generation DES (SES and PES, ZES), EES showed similar one-year clinical outcomes in terms of MACE in patients with STEMI following primary PCI and no stent thrombosis.

	EES (n=197)	ZES (n=203)	SES (n=203)	PES (n=194)	P Value
MACE, N (%)	6 (3.1)	12 (5.9)	7 (3.4)	11 (5.7)	0.322
Cardiac death, N (%)	2 (1.0)	5 (2.5)	3 (1.5)	2 (1.0)	0.646
Recurrent MI, N (%)	1 (0.5)	2 (1.0)	4 (2.0)	6 (3.1)	0.781
Ischemia-driven TLR, N (%)	3 (1.5)	5 (2.5)	0	3 (1.5)	0.190
Stent thrombosis, N (%)	0	4 (2.0)	4 (2.0)	4 (2.0)	0.719